1. Arachidonic Acid Metabolism Pathway Is Not Only Dominant in Metabolic Modulation but Associated With Phenotypic Variation After Acute Hypoxia Exposure
    Chang Liu et al, 2018, Front. Physiol. CrossRef
  2. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study
    Xue-Fen Lei et al, 2018, WJCC CrossRef
  3. Bioanalytical insights into the association between eicosanoids and pathogenesis of hepatocellular carcinoma
    Yong-Jiang Xu et al, 2018, Cancer Metastasis Rev CrossRef
  4. Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention
    Bee Luan Khoo et al, 2019, Br J Cancer CrossRef
  5. Cyclooxygenase-2 in gastrointestinal malignancies
    Ganji Purnachandra Nagaraju et al, 2019, Cancer CrossRef
  6. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma
    Atsunori Tsuchiya et al, 2019, Heliyon CrossRef
  7. Prognostic Analysis of HCC With HCV Infection Using Epithelial-Mesenchymal Transition Gene Profiles
    Masaki Ueno et al, 2020, Journal of Surgical Research CrossRef
  8. Development of a18F-labeled Diaryl-Substituted Dihydropyrrolo[3,2,1-hi]indole as Potential Probe for Functional Imaging of Cyclooxygenase-2 with PET
    Cemena Gassner et al, 2016, ChemistrySelect CrossRef
  9. DEC1 promotes hypoxia-induced epithelial-mesenchymal transition (EMT) in human hepatocellular carcinoma cells
    Keishu MURAKAMI et al, 2017, Biomed. Res. CrossRef
  10. References
    , 2017 CrossRef
  11. Plantamajoside inhibits the proliferation and epithelial‐to‐mesenchymal transition in hepatocellular carcinoma cells via modulating hypoxia‐inducible factor‐1α‐dependent gene expression
    Wenzhe Yin et al, 2020, Cell Biol Int CrossRef
  12. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies
    Lei Chang et al, 2017, Oncotarget CrossRef
  13. COX-2 induces apoptosis-resistance in hepatocellular carcinoma cells via the HIF-1α/PKM2 pathway.
    Qin Wang et al, 2019, Int J Mol Med CrossRef
  14. Mechanism for hypoxia inducible factor-1α to promote immune escape and therapeutic tolerance in hepatocellular carcinoma under hypoxic microenvironment
    Huan-Zhen Yang et al, 2020, WCJD CrossRef
  15. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma
    Zhi-Huan Lin et al, 2020, Clin Exp Med CrossRef
  16. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study.
    Liyun Zheng et al, 2020, Front Mol Biosci CrossRef
  17. Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis.
    Zi-Niu Ding et al, 2021, J Gastroenterol Hepatol CrossRef
  18. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model
    Bleuenn Brusset et al, 2021, Cancers CrossRef
  19. Intersecting Mechanisms of Hypoxia and Prostaglandin E2-Mediated Inflammation in the Comparative Biology of Oral Squamous Cell Carcinoma
    Walaa Hamed Shaker Nasry et al, 2021, Front. Oncol. CrossRef
  20. The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition
    Fernán Gómez-Valenzuela et al, 2021, Front. Oncol. CrossRef
  21. Role of eicosanoids in liver repair, regeneration and cancer
    María de Luján Alvarez et al, 2021, Biochemical Pharmacology CrossRef
  22. HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma
    Minjiang Chen et al, 2022, Biomaterials CrossRef
  23. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma
    Qifan He et al, 2022, Front. Immunol. CrossRef
  24. Levosimendan Ameliorates Cardiopulmonary Function but Not Inflammatory Response in a Dual Model of Experimental ARDS
    René Rissel et al, 2022, Biomedicines CrossRef
  25. Toxic metals in the regulation of epithelial-mesenchymal plasticity: demons or angels?
    Andy T. Y. Lau, 0 CrossRef
  26. Hypoxia‑inducible factor‑1α: A critical target for inhibiting the metastasis of hepatocellular carcinoma (Review)
    Huan Chen et al, 2022, Oncol Lett CrossRef
  27. Serum alanine aminotransferase to hemoglobin ratio and radiological features predict the prognosis of postoperative adjuvant TACE in patients with hepatocellular carcinoma
    Zicong Xia et al, 2022, Front. Oncol. CrossRef
  28. A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE
    Zicong Xia et al, 2022, Journal of Oncology CrossRef
  29. A VEGFR targeting peptide-drug conjugate (PDC) suppresses tumor angiogenesis in a TACE model for hepatocellular carcinoma therapy
    Dongyuan Wang et al, 2022, Cell Death Discov. CrossRef
  30. Proteoglycan-4 predicts good prognosis in patients with hepatocellular carcinoma receiving transcatheter arterial chemoembolization and inhibits cancer cell migration in vitro
    Yuan Guo et al, 2022, Front. Oncol. CrossRef
  31. Value of biomarkers in epithelial–mesenchymal transition models of liver cancer under different interventions: a meta-analysis
    Jing Yan et al, 2023, Future Oncology CrossRef
  32. Recent Progress in Advanced Hydrogel‐Based Embolic Agents: From Rational Design Strategies to Improved Endovascular Embolization
    Xiaohong Li et al, 2023, Adv Healthcare Materials CrossRef
  33. Hypoxia-Regulated Gene Expression and Metastasis
    Ayfer Karlitepe et al, 2023 CrossRef
  34. Targeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma
    Kenneth N. Huynh et al, 2023, Cancers CrossRef
  35. Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway
    Eman H. Yousef et al, 2023, Translational Research CrossRef
  36. Hypothetical hypoxia-driven rapid disease progression in hepatocellular carcinoma post transarterial chemoembolization: A case report
    Kai-Fuan Yeo et al, 2023, World J Clin Cases CrossRef
  37. Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
    Fei Cao et al, 2023, BMC Cancer CrossRef
  38. Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study
    Ya Gao et al, 2023, Front. Oncol. CrossRef
  39. Anti-cancer activity and cellular uptake of 7,3′,4′- and 7,8,4′-trihydroxyisoflavone in HepG2 cells under hypoxic conditions
    Wen-Sheng Tzeng et al, 2024, Journal of Enzyme Inhibition and Medicinal Chemistry CrossRef
  40. Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure
    Jiahao Li et al, 2024, Life Sciences CrossRef
  41. Hypoxia as a Target for Combination with Transarterial Chemoembolization in Hepatocellular Carcinoma
    Zizhuo Wang et al, 2024, Pharmaceuticals CrossRef
  42. Assessment of using heart of date palm as a new source of protein and carbohydrate on the quality of low-fat bio fermented camel milk and its potential anticancer properties
    Wael F. Elkot et al, 2024, International Journal of Biological Macromolecules CrossRef
  43. Reprogramming of Glucose Metabolism for Revisiting Hepatocellular Carcinoma Resistance to Transcatheter Hepatic Arterial Chemoembolization
    Ruijie Zhang et al, 2024, ChemBioChem CrossRef